Phylogeny  
• Kinome lineage: Protein Tyrosine Kinase group → Eph family → EphA subclass → EPHA7 (choi2009discoveryandstructural pages 1-2, toracchio2024epha2incancer pages 14-16).  
• Orthologs: Mus musculus Epha7 (gale1996ephreceptorsand pages 11-11), Gallus gallus Epha7 in limb buds (toracchio2024epha2incancer pages 14-16), Danio rerio epha7a/epha7b (buckens2020theroleof pages 31-34), Xenopus Epha7 (gale1996ephreceptorsand pages 11-11), ancestral Drosophila Eph (buckens2020theroleof pages 31-34).  
• Closest paralogs: EPHA6 and EPHA4 within the EphA branch (toracchio2024epha2incancer pages 14-16).  

Reaction Catalyzed  
ATP + protein-L-tyrosine → ADP + protein-L-tyrosine-phosphate (chakraborty2021crystalstructureof pages 5-6).  

Cofactor Requirements  
Mg²⁺ is required; coordinated by Asp776 of the DFG motif (choi2009discoveryandstructural pages 4-5).  

Substrate Specificity  
• Eph kinases preferentially target tyrosines flanked by acidic residues; consensus motif D/E-x-pY-x-D/E (toracchio2024epha2incancer pages 14-16, gale1996ephreceptorsand pages 11-11).  
• No EPHA7-specific divergence from this pattern has been reported (toracchio2024epha2incancer pages 14-16).  

Structure  
• Domain order: ligand-binding → cysteine-rich → 2 × fibronectin-III → transmembrane → juxtamembrane → kinase → SAM → PDZ-binding motif (toracchio2024epha2incancer pages 1-2, gale1996ephreceptorsand pages 11-11).  
• 2.0 Å crystal structure with inhibitor 9 shows inactive DFG-out conformation and enlarged hydrophobic pocket (choi2009discoveryandstructural pages 2-4).  
• Catalytic triad: Lys665–Glu682 salt bridge and Asp776 in the DFG motif (chakraborty2021crystalstructureof pages 5-6, choi2009discoveryandstructural pages 4-5).  
• Activation loop Tyr791 undergoes autophosphorylation for full activity (li2017liganddependentepha7signaling pages 8-9).  
• Gatekeeper Ile707 removes a hinge H-bond accepted by Thr in other EphA kinases, reducing affinity for some type II inhibitors (choi2009discoveryandstructural pages 4-5).  
• Pathogenic mutants Gly656Arg/Glu and Asp751His distort the N-lobe and weaken ATP binding (chakraborty2021crystalstructureof pages 5-6).  

Regulation  
• Tyr791 autophosphorylation activates kinase and tumour-suppressive signalling (li2017liganddependentepha7signaling pages 8-9).  
• Juxtamembrane tyrosine phosphorylation relieves autoinhibition after ephrin binding (gale1996ephreceptorsand pages 11-11).  
• Cbl-mediated ubiquitination targets receptor for degradation (toracchio2024epha2incancer pages 14-16).  
• ADAM10-dependent ectodomain shedding reduces surface receptor levels (toracchio2024epha2incancer pages 14-16).  
• Additional serine/threonine phosphorylation events modulate turnover and pathway choice (gale1996ephreceptorsand pages 11-11).  
• Ligand-induced oligomerisation drives DFG-in ↔ DFG-out transitions captured structurally (choi2009discoveryandstructural pages 2-4).  

Function  
• Expression: enriched in developing and adult CNS (gale1996ephreceptorsand pages 11-11, leonard2020epha7isoformsdifferentially pages 21-22); present in prostate and other epithelia (guan2009aberrantmethylationof pages 7-7).  
• Ligand binding: high-affinity interaction with ephrin-A5; initiates bidirectional signalling (gale1996ephreceptorsand pages 11-11).  
• Downstream effects: inhibits PI3K/Akt (reduced Akt-Thr308/Ser473 phosphorylation) and shifts Bax/Bcl-2 toward apoptosis (li2017liganddependentepha7signaling pages 8-9); activates ERK and Rho GTPases via SHC1 and VAV2 adaptors (buckens2020theroleof pages 31-34).  
• Interactors: SHC1, VAV2 (buckens2020theroleof pages 31-34); TNFR1 (li2017liganddependentepha7signaling pages 8-9); focal adhesion kinase in integrin complexes (wilkinson2001multiplerolesof pages 10-10).  
• Biological roles: axon repulsion in corticothalamic and retinocollicular mapping (gale1996ephreceptorsand pages 11-11); regulation of cortical dendrite growth by kinase-active versus truncated isoforms (leonard2020epha7isoformsdifferentially pages 21-22); caspase-3-dependent apoptosis in neural progenitors and prostate cancer cells (li2017liganddependentepha7signaling pages 8-9).  

Inhibitors  
• Type II inhibitors 6 and 9 bind the DFG-out pocket; compound 9 shows nanomolar inhibition of EPHA7 despite reduced affinity from Ile707 gatekeeper (choi2009discoveryandstructural pages 2-4, choi2009discoveryandstructural pages 4-5).  
• Broad-spectrum RTK inhibitors nilotinib and dasatinib exhibit measurable activity in profiling assays (choi2009discoveryandstructural pages 1-2).  

Other Comments  
• Promoter hypermethylation associates with aggressive prostate cancer (guan2009aberrantmethylationof pages 7-7).  
• Haploinsufficiency or focal deletions cause neurodevelopmental disorders with microcephaly and intellectual disability (levy2021epha7haploinsufficiencyis pages 1-2).  
• Somatic mutations Gly656Arg, Gly656Glu and Asp751His reduce catalytic efficiency and are linked to cancer (chakraborty2021crystalstructureof pages 5-6).  
• EPHA7 deregulation via methylation or mutation is reported in colorectal, lung, melanoma and osteosarcoma (chakraborty2021crystalstructureof pages 6-6, toracchio2024epha2incancer pages 14-16).

References

1. (choi2009discoveryandstructural pages 1-2): Yongmun Choi, F. Syeda, J. Walker, P. Finerty, D. Cuerrier, Amy Wojciechowski, Qingsong Liu, S. Dhe-Paganon, and N. Gray. Discovery and structural analysis of eph receptor tyrosine kinase inhibitors. Bioorganic & medicinal chemistry letters, 19 15:4467-70, Aug 2009. URL: https://doi.org/10.1016/j.bmcl.2009.05.029, doi:10.1016/j.bmcl.2009.05.029. This article has 109 citations.

2. (toracchio2024epha2incancer pages 14-16): Lisa Toracchio, Marianna Carrabotta, Caterina Mancarella, Andrea Morrione, and Katia Scotlandi. Epha2 in cancer: molecular complexity and therapeutic opportunities. International Journal of Molecular Sciences, 25:12191, Nov 2024. URL: https://doi.org/10.3390/ijms252212191, doi:10.3390/ijms252212191. This article has 4 citations and is from a peer-reviewed journal.

3. (chakraborty2021crystalstructureof pages 5-6): Shubhashish Chakraborty and A. Varma. Crystal structure of clinically reported mutations gly656arg, gly656glu and asp751his identified in the kinase domain of epha7. Biochemical and biophysical research communications, 568:62-67, Jun 2021. URL: https://doi.org/10.1016/j.bbrc.2021.06.048, doi:10.1016/j.bbrc.2021.06.048. This article has 2 citations and is from a peer-reviewed journal.

4. (gale1996ephreceptorsand pages 11-11): Nicholas W Gale, Sacha J Holland, David M Valenzuela, Ann Flenniken, Li Pan, Terrence E Ryan, Mark Henkemeyer, Klaus Strebhardt, Hisamaru Hirai, David G Wilkinson, Tony Pawson, Samuel Davis, and George D Yancopoulos. Eph receptors and ligands comprise two major specificity subclasses and are reciprocally compartmentalized during embryogenesis. Neuron, 17:9-19, Jul 1996. URL: https://doi.org/10.1016/s0896-6273(00)80276-7, doi:10.1016/s0896-6273(00)80276-7. This article has 889 citations and is from a highest quality peer-reviewed journal.

5. (toracchio2024epha2incancer pages 1-2): Lisa Toracchio, Marianna Carrabotta, Caterina Mancarella, Andrea Morrione, and Katia Scotlandi. Epha2 in cancer: molecular complexity and therapeutic opportunities. International Journal of Molecular Sciences, 25:12191, Nov 2024. URL: https://doi.org/10.3390/ijms252212191, doi:10.3390/ijms252212191. This article has 4 citations and is from a peer-reviewed journal.

6. (buckens2020theroleof pages 31-34): Oscar J Buckens, Btissame El Hassouni, Elisa Giovannetti, and Godefridus J Peters. The role of eph receptors in cancer and how to target them: novel approaches in cancer treatment. Expert Opinion on Investigational Drugs, 29:567-582, May 2020. URL: https://doi.org/10.1080/13543784.2020.1762566, doi:10.1080/13543784.2020.1762566. This article has 70 citations and is from a peer-reviewed journal.

7. (chakraborty2021crystalstructureof pages 6-6): Shubhashish Chakraborty and A. Varma. Crystal structure of clinically reported mutations gly656arg, gly656glu and asp751his identified in the kinase domain of epha7. Biochemical and biophysical research communications, 568:62-67, Jun 2021. URL: https://doi.org/10.1016/j.bbrc.2021.06.048, doi:10.1016/j.bbrc.2021.06.048. This article has 2 citations and is from a peer-reviewed journal.

8. (choi2009discoveryandstructural pages 2-4): Yongmun Choi, F. Syeda, J. Walker, P. Finerty, D. Cuerrier, Amy Wojciechowski, Qingsong Liu, S. Dhe-Paganon, and N. Gray. Discovery and structural analysis of eph receptor tyrosine kinase inhibitors. Bioorganic & medicinal chemistry letters, 19 15:4467-70, Aug 2009. URL: https://doi.org/10.1016/j.bmcl.2009.05.029, doi:10.1016/j.bmcl.2009.05.029. This article has 109 citations.

9. (choi2009discoveryandstructural pages 4-5): Yongmun Choi, F. Syeda, J. Walker, P. Finerty, D. Cuerrier, Amy Wojciechowski, Qingsong Liu, S. Dhe-Paganon, and N. Gray. Discovery and structural analysis of eph receptor tyrosine kinase inhibitors. Bioorganic & medicinal chemistry letters, 19 15:4467-70, Aug 2009. URL: https://doi.org/10.1016/j.bmcl.2009.05.029, doi:10.1016/j.bmcl.2009.05.029. This article has 109 citations.

10. (guan2009aberrantmethylationof pages 7-7): Ming Guan, Chong Xu, Fanglin Zhang, and Chuanzhong Ye. Aberrant methylation of <i>epha7</i> in human prostate cancer and its relation to clinicopathologic features. International Journal of Cancer, 124:88-94, Sep 2009. URL: https://doi.org/10.1002/ijc.23890, doi:10.1002/ijc.23890. This article has 68 citations and is from a domain leading peer-reviewed journal.

11. (leonard2020epha7isoformsdifferentially pages 21-22): Carrie E. Leonard, Maryna Baydyuk, Marissa A. Stepler, Denver A. Burton, and M. Donoghue. Epha7 isoforms differentially regulate cortical dendrite development. PLoS ONE, Mar 2020. URL: https://doi.org/10.1101/2020.03.27.011486, doi:10.1101/2020.03.27.011486. This article has 10 citations and is from a peer-reviewed journal.

12. (levy2021epha7haploinsufficiencyis pages 1-2): Jonathan Lévy, Bérénice Schell, Hala Nasser, Myriam Rachid, Lyse Ruaud, Nathalie Couque, Patrick Callier, Laurence Faivre, Nathalie Marle, Aafke Engwerda, Conny M. A. van Ravenswaaij‐Arts, Morgane Plutino, Houda Karmous‐Benailly, Caroline Benech, Sylvia Redon, Odile Boute, Elise Boudry Labis, Mélanie Rama, Paul Kuentz, Jessica Assoumani, Lionel Van Maldergem, Céline Dupont, Alain Verloes, and Anne‐Claude Tabet. <scp>epha7</scp> haploinsufficiency is associated with a neurodevelopmental disorder. Clinical Genetics, 100:396-404, Jul 2021. URL: https://doi.org/10.1111/cge.14017, doi:10.1111/cge.14017. This article has 8 citations and is from a peer-reviewed journal.

13. (li2017liganddependentepha7signaling pages 8-9): Shibao Li, Zhiyuan Wu, P. Ma, Yinhai Xu, Yuming Chen, Hua Wang, P. He, Z. Kang, L. Yin, Yao Zhao, Xin-ju Zhang, Xiao Xu, Xiaochao Ma, and M. Guan. Ligand-dependent epha7 signaling inhibits prostate tumor growth and progression. Cell Death & Disease, Oct 2017. URL: https://doi.org/10.1038/cddis.2017.507, doi:10.1038/cddis.2017.507. This article has 46 citations.

14. (wilkinson2001multiplerolesof pages 10-10): D. Wilkinson. Multiple roles of eph receptors and ephrins in neural development. Nature Reviews Neuroscience, 2:155-164, Mar 2001. URL: https://doi.org/10.1038/35058515, doi:10.1038/35058515. This article has 824 citations and is from a highest quality peer-reviewed journal.
